Replicel Life Sciences Stock Today
| RP Stock | CAD 0.01 0.00 0.00% |
Performance0 of 100
| Odds Of DistressOver 65
|
RepliCel Life is selling for under 0.01 as of the 18th of December 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.01. RepliCel Life has more than 65 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of November 2024 and ending today, the 18th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. REPLICEL LIFE operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.. The company has 73.58 M outstanding shares of which 520 shares are at this time shorted by private and institutional investors with about 0.01 trading days to cover. More on RepliCel Life Sciences
Moving together with RepliCel Stock
Moving against RepliCel Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
RepliCel Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. RepliCel Life's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding RepliCel Life or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Andrew Schutte | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
RepliCel Life's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to RepliCel Life's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsRepliCel Life can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand RepliCel Life's financial leverage. It provides some insight into what part of RepliCel Life's total assets is financed by creditors.
| |||||
RepliCel Life Sciences (RP) is traded on TSX Venture Exchange in Canada and employs 8 people. RepliCel Life is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 735.78 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate RepliCel Life's market, we take the total number of its shares issued and multiply it by RepliCel Life's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. RepliCel Life Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 73.58 M outstanding shares of which 520 shares are at this time shorted by private and institutional investors with about 0.01 trading days to cover.
RepliCel Life Sciences currently holds about 1.16 M in cash with (1.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check RepliCel Life Probability Of Bankruptcy
Ownership AllocationRepliCel Life owns a total of 73.58 Million outstanding shares. RepliCel Life has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check RepliCel Ownership Details
RepliCel Life Sciences Risk Profiles
Although RepliCel Life's alpha and beta are two of the key measurements used to evaluate RepliCel Life's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 7.37 | |||
| Standard Deviation | 21.02 | |||
| Variance | 441.99 | |||
| Risk Adjusted Performance | (0.02) |
RepliCel Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in RepliCel Life without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
RepliCel Life Corporate Management
Elected by the shareholders, the RepliCel Life's board of directors comprises two types of representatives: RepliCel Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RepliCel. The board's role is to monitor RepliCel Life's management team and ensure that shareholders' interests are well served. RepliCel Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RepliCel Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA CPA | Chief Officer | Profile | |
| Kevin McElwee | Chief Scientific Officer | Profile | |
| MSc PMP | Clinical Consultant | Profile | |
| Ben Austring | Corporate Officer | Profile | |
| David CPA | Chief Officer | Profile | |
| BEd LLB | Corp Director | Profile |
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.